Drug-drug interaction between pitavastatin and various drugs via OATP1B1

Drug Metabolism and Disposition

Volumn 34, Issue 7, 2006, Pages 1229-1236

  Hirano, Masaru ^a   Maeda, Kazuya ^a   Shitara, Yoshihisa ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHLORZOXAZONE; CIMETIDINE; CIPROFIBRATE; CLARITHROMYCIN; CLOFIBRATE; COLCHICINE; CYCLOSPORIN A; ERYTHROMYCIN; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; FENOFIBRATE; FLUCONAZOLE; GEMFIBROZIL; GLIBENCLAMIDE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; PHENYTOIN; PITAVASTATIN; RANITIDINE; RIFAMPICIN; RIFAMYCIN; TACROLIMUS; TELMISARTAN; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METABOLISM; METHODOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE; CYCLOSPORINE; DRUG INTERACTIONS; ESTRADIOL; ESTRONE; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; QUINOLINES; TRANSFECTION;

EID: 33745243715     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009290     Document Type: Article

References (35)

1. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, et al. (1997) Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsch 47:904-909.
2. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
3. Campbell SD, de Morais SM, and Xu JJ (2004) Inhibition of human organic anion transporting polypeptide OATP1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem-Biol Interact 150:179-187.
4. Clark WG, Brater DC, Johnson AR, and Goth A (1992) Goth's Medical Pharmacology, 13th ed, Mosby-Year Book, St. Louis.
5. Evans M and Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25:649-663.
6. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
7. Hardman J, Limbird L, and Gilman AG (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, McGraw-Hill, New York.
8. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, Iijima H, and Saito Y (2003) The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med 19:381-389.
9. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146.
10. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, and Okuyama A (2001) Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158:417-423.
11. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109-1115.
12. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
13. Kajinami K, Takekoshi N, and Saito Y (2003) Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 21:199-215.
14. Kantola T, Kivisto KT, and Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177-182.
15. Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yonemitsu M, and Yanagawa Y (1998) Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase: I. Absorption, distribution, metabolism and excretion in rats. Xenobiol Metab Dispos 13:484-498.
16. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703-708.
17. Kojima J, Ohshima T, Yoneda M, and Sawada H (2001) Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs. Xenobio Metab Dispos 16:497-502.
18. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
19. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-267
20. Mathew P, Cuddy T, Tracewell WG, and Salazar D (2004) An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther 75:33.
21. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, and Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double transfected MDCKII cells expressing human OATP1B1/MRP2, OATP1B1/MDR1 and OATP1B1/BCRP. J Pharmacol Exp Ther 314:1059-1067.
22. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461.
23. Neuvonen PJ, Kantola T, and Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
24. Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438-445.
25. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, and Christians U (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311-321.
26. Sasaki M, Suzuki H, Ito K, Abe T, and Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497-6503.
27. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, and Sugiyama Y (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481.
28. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
29. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
30. Shitara Y, Sato H, and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723.
31. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177.
32. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, and Sugiyama Y (2001) Characterization of the efflux transport of 17beta-estradiol-D-17betaglucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 298:316-322.
33. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res (NY) 18:1262-1269.
34. Williams D and Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370.
35. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.